AU2014370697B2 - Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease - Google Patents

Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease Download PDF

Info

Publication number
AU2014370697B2
AU2014370697B2 AU2014370697A AU2014370697A AU2014370697B2 AU 2014370697 B2 AU2014370697 B2 AU 2014370697B2 AU 2014370697 A AU2014370697 A AU 2014370697A AU 2014370697 A AU2014370697 A AU 2014370697A AU 2014370697 B2 AU2014370697 B2 AU 2014370697B2
Authority
AU
Australia
Prior art keywords
compound
branched
straight
benzyloxy
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014370697A
Other languages
English (en)
Other versions
AU2014370697A1 (en
Inventor
Jin Wook Chung
Jeong Ho Im
In Geun Jo
Ku Suk Kang
Jin Young Kim
Sang Ku Yoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaceum Inc
Original Assignee
Glaceum Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaceum Inc filed Critical Glaceum Inc
Publication of AU2014370697A1 publication Critical patent/AU2014370697A1/en
Assigned to GLACEUM, INC. reassignment GLACEUM, INC. Request for Assignment Assignors: ERUM BIOTECHNOLOGIES, INC.
Application granted granted Critical
Publication of AU2014370697B2 publication Critical patent/AU2014370697B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2014370697A 2013-12-24 2014-12-23 Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease Active AU2014370697B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2013-0162909 2013-12-24
KR20130162909 2013-12-24
KR10-2014-0181951 2014-12-17
KR1020140181951A KR102344479B1 (ko) 2013-12-24 2014-12-17 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물
PCT/KR2014/012688 WO2015099392A1 (ko) 2013-12-24 2014-12-23 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
AU2014370697A1 AU2014370697A1 (en) 2016-06-16
AU2014370697B2 true AU2014370697B2 (en) 2017-01-19

Family

ID=53788040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014370697A Active AU2014370697B2 (en) 2013-12-24 2014-12-23 Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease

Country Status (21)

Country Link
US (1) US9783551B2 (enExample)
EP (1) EP3098224B1 (enExample)
JP (2) JP6620096B2 (enExample)
KR (1) KR102344479B1 (enExample)
CN (1) CN105849111B (enExample)
AU (1) AU2014370697B2 (enExample)
BR (1) BR112016011281B1 (enExample)
CA (1) CA2929001C (enExample)
CY (1) CY1121554T1 (enExample)
DK (1) DK3098224T3 (enExample)
ES (1) ES2718878T3 (enExample)
HR (1) HRP20190573T1 (enExample)
HU (1) HUE043902T2 (enExample)
IL (1) IL245908B (enExample)
MX (1) MX374944B (enExample)
NZ (1) NZ720328A (enExample)
PL (1) PL3098224T3 (enExample)
PT (1) PT3098224T (enExample)
SG (1) SG11201604371PA (enExample)
TW (1) TWI585093B (enExample)
WO (1) WO2015099392A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102344479B1 (ko) * 2013-12-24 2021-12-29 주식회사 글라세움 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물
SG11201811796SA (en) * 2016-06-29 2019-02-27 Glaceum Inc Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same
JP6810275B2 (ja) 2016-10-04 2021-01-06 グラセウム・インコーポレイテッド ３−フェニル−２，３，４，８，９，１０−ヘキサヒドロピラノ［２，３−ｆ］クロメン誘導体およびその光学異性体の合成方法
TWI804600B (zh) 2018-04-03 2023-06-11 南韓商格雷森伍股份有限公司 3-苯基-2,8-二氫吡喃[2,3-ƒ]苯并哌喃衍生物的合成方法
KR20190116099A (ko) 2018-04-03 2019-10-14 주식회사 글라세움 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체 및 이를 포함하는 약학적 조성물
KR20200105198A (ko) 2019-02-28 2020-09-07 주식회사 글라세움 신경계 질환의 예방 또는 치료용 약학적 조성물
KR102692932B1 (ko) 2019-07-30 2024-08-07 주식회사 글라세움 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법
KR20220166203A (ko) 2021-06-08 2022-12-16 주식회사 글라세움 퇴행성 안질환의 예방 또는 치료용 약학적 조성물
CN113616548B (zh) * 2021-09-02 2023-04-28 河南科技大学 一种水溶性光甘草定包合物及其制备方法
US20250250279A1 (en) 2022-04-12 2025-08-07 Glaceum Inc. METHOD FOR SYNTHESIZING 3-PHENYL-2,3,4,8,9,10-HEXAHYDROPYRANO[2,3-f]CHROMENE DERIVATIVES
CN114903879B (zh) * 2022-06-23 2023-10-31 东北大学 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途
WO2024151017A1 (ko) 2023-01-12 2024-07-18 주식회사 글라세움 퇴행성 골관절염의 예방 또는 치료용 약학적 조성물
KR20250081177A (ko) 2023-11-29 2025-06-05 한국화학연구원 Hsg4112 r형을 유효성분으로 포함하는 반려동물의 비만 예방, 개선 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070052211A (ko) * 2005-11-16 2007-05-21 주식회사 엠디바이오알파 글라브리딘을 유효성분으로 함유하는 질환 증후군 예방 및치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1440688A4 (en) 2001-10-11 2005-11-30 Kaneka Corp PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR LIGANDS AND METHOD OF MANUFACTURING THE SAME
KR100565423B1 (ko) * 2003-10-20 2006-03-30 빅 바이오 주식회사 이소플라반 유도체 또는 이소플라벤 유도체의 제조방법
JP2006008604A (ja) * 2004-06-25 2006-01-12 Kuraray Co Ltd イソフラバン誘導体の製造方法
KR102344479B1 (ko) * 2013-12-24 2021-12-29 주식회사 글라세움 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070052211A (ko) * 2005-11-16 2007-05-21 주식회사 엠디바이오알파 글라브리딘을 유효성분으로 함유하는 질환 증후군 예방 및치료용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NEHRY, O. ET AL., J. Agric. Food. Chem., 2003, Vol. 51, pages 1201-1207 *
VAN HEERDEN, F. R. ET AL., Journal of the Chemical Society, Perkin Transactions 1: ;Organic and Bio-Organic Chemistry,1978, (2), pages 137-145 *
WU, F. ET AL, Molecular Medicine Reports, 2013, Vol. 7, pages 1278-1282 *

Also Published As

Publication number Publication date
EP3098224A1 (en) 2016-11-30
PT3098224T (pt) 2019-04-26
JP6620096B2 (ja) 2019-12-11
EP3098224B1 (en) 2019-01-30
CN105849111A (zh) 2016-08-10
TW201607949A (zh) 2016-03-01
DK3098224T3 (da) 2019-05-13
US9783551B2 (en) 2017-10-10
JP2018135343A (ja) 2018-08-30
MX374944B (es) 2025-03-06
ES2718878T3 (es) 2019-07-05
HUE043902T2 (hu) 2019-10-28
CA2929001C (en) 2018-02-20
AU2014370697A1 (en) 2016-06-16
PL3098224T3 (pl) 2019-07-31
TWI585093B (zh) 2017-06-01
KR20150075030A (ko) 2015-07-02
JP2017501163A (ja) 2017-01-12
KR102344479B1 (ko) 2021-12-29
BR112016011281B1 (pt) 2021-11-16
CN105849111B (zh) 2018-05-04
BR112016011281A2 (enExample) 2017-08-08
CA2929001A1 (en) 2015-07-02
HRP20190573T1 (hr) 2019-05-17
IL245908A0 (en) 2016-08-02
NZ720328A (en) 2018-02-23
WO2015099392A1 (ko) 2015-07-02
MX2016008429A (es) 2017-02-23
SG11201604371PA (en) 2016-07-28
IL245908B (en) 2020-08-31
CY1121554T1 (el) 2020-05-29
EP3098224A4 (en) 2017-07-05
US20160272650A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
AU2014370697B2 (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
JP7036871B2 (ja) 光学活性ピラノクロメニルフェノール誘導体およびそれを含む薬学的組成物
KR20080027191A (ko) 신규한 벤즈옥사졸 유도체, 이의 제조방법 및 이를포함하는 약학 조성물
JP6977053B2 (ja) ギ酸またはその薬学的に許容可能な塩を有効成分として含む肥満または肥満によって惹起された代謝症候群の予防または治療用組成物
KR101457637B1 (ko) 디히드로피라졸카르보티오아미드 유도체 및 그 제법 및 그 유도체를 포함하는 항암제 조성물
WO2020092376A1 (en) Treating non-alcoholic steatohepatitis (nash)
HK1227863A1 (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
HK1227863B (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
NZ749461B (en) Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same
HK40004723B (zh) 旋光性吡喃并色烯基苯酚衍生物及包含其的药物组合物
HK40004723A (en) Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GLACEUM, INC.

Free format text: FORMER APPLICANT(S): ERUM BIOTECHNOLOGIES, INC.

FGA Letters patent sealed or granted (standard patent)